CCA
PFE icon

Cygnus Capital Advisors’s Pfizer PFE Stock Holding History

Cygnus Capital Advisors’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.52M Sell
104,460
-38,340
-27% -$1M 1.71% 25
2026
Q1 		$4.01M Buy
142,800
+2,700
+2% +$71.9K 2.74% 8
2025
Q4 		$3.49M Buy
+140,100
New +$3.53M 2.55% 6

Other funds holding PFE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Cygnus Capital Advisors's PFE Position: Q2 2026 in Review

Cygnus Capital Advisors reduced its Pfizer (PFE) stake by 27% in Q2 2026, selling an estimated $1M and leaving 104,460 shares worth $2.52M. The position accounts for 1.71% of the portfolio, ranked #25.

Cygnus Capital Advisors first reported a position in PFE in Q4 2025 and has held it in 3 quarters since. The position peaked at $4.01M in Q1 2026. 2,840 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Cygnus Capital Advisors held 104,460 shares of Pfizer worth $2.52M as of Q2 2026.
  • Cygnus Capital Advisors sold 38,340 Pfizer shares in Q2 2026, an estimated $1M.
  • Pfizer made up 1.71% of Cygnus Capital Advisors's portfolio in Q2 2026, its #25 holding.
  • Cygnus Capital Advisors first reported a position in Pfizer in Q4 2025 and has held it in 3 quarters since.
  • Cygnus Capital Advisors's Pfizer position peaked at $4.01M in Q1 2026.
  • 2,840 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Cygnus Capital Advisors's 13F filing for Q2 2026, filed 3 Sep 2026.